Quoin (QNRX) grants CEO Michael Myers 318,750 ADS options

Rhea-AI Filing Summary

Quoin Pharmaceuticals (QNRX) reported an equity award to its CEO and director, Michael Myers. On February 4, 2026, he received a share option covering 318,750 American Depositary Shares (ADSs) at an exercise price of $7.37 per ADS, with no purchase price paid for the grant itself.

The option becomes exercisable in four annual installments: 20% of the ADSs vest on each of February 4, 2027, 2028 and 2029, and 40% vest on February 4, 2030. The option expires on February 4, 2036 and is held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Myers Michael

(Last) (First) (Middle)

C/O QUOIN PHARMACEUTICALS LTD.,

42127 PLEASANT FOREST COURT

(Street)

ASHBURN VA 20148

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quoin Pharmaceuticals, Ltd. [ QNRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$7.37(1)	02/04/2026		A		318,750(1)		(2)	02/04/2036	ADS	318,750(1)	$0	318,750(1)	D

Explanation of Responses:

1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

2. The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

	/s/ Michael Myers	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Quoin Pharmaceuticals (QNRX) disclose in this Form 4?

Quoin Pharmaceuticals disclosed a stock option grant to CEO and director Michael Myers. He received options on 318,750 American Depositary Shares, recorded as an acquisition transaction on February 4, 2026, with the options held directly after the grant.

How many Quoin Pharmaceuticals (QNRX) ADSs are covered by Michael Myers’ new option?

The option granted to Michael Myers covers 318,750 American Depositary Shares. This entire amount is reflected as beneficially owned in derivative form following the transaction, according to the Form 4’s Table II and the recorded post-transaction balance of 318,750 derivative securities.

What is the exercise price of Michael Myers’ Quoin (QNRX) stock option?

The exercise price of Michael Myers’ stock option is $7.37 per American Depositary Share. The filing specifies that both the number of underlying securities and the exercise price are stated in ADS terms, with each ADS representing thirty-five ordinary shares.

How does the vesting schedule work for Michael Myers’ Quoin (QNRX) option grant?

The option vests in four annual installments. Twenty percent of the ADSs vest on each of February 4, 2027, February 4, 2028 and February 4, 2029, and the remaining forty percent vests on February 4, 2030, as detailed in the footnote.

When does Michael Myers’ Quoin Pharmaceuticals (QNRX) option grant expire?

The CEO’s option grant expires on February 4, 2036. The Form 4 lists this expiration date in Table II, indicating the long-term nature of the incentive, with the option remaining exercisable until that date subject to its vesting schedule.

What does each Quoin Pharmaceuticals (QNRX) ADS represent in this Form 4 filing?

Each American Depositary Share referenced in the option represents thirty-five ordinary shares of Quoin Pharmaceuticals. The filing explains that both the number of securities underlying the option and the exercise price are expressed in ADS terms to reflect this depositary share structure.